Parallel imports of pharmaceutical products in the European Union

Parallel imports are legitimately produced goods imported legally into a country without the authorization of a trademark, copyright, or patent holder. In the European Union, so long as a pharmaceutical manufacturer has placed a good on the market voluntarily, the principle of free movement of goods...

Full description

Bibliographic Details
Main Author: Ganslandt, Mattias
Corporate Author: World Bank Development Research Group
Other Authors: Maskus, Keith Eugene
Format: eBook
Language:English
Published: Washington, D.C World Bank, Development Research Group, Trade 2001
Series:Policy research working paper
Subjects:
Online Access:
Collection: World Bank E-Library Archive - Collection details see MPG.ReNa
LEADER 01798nmm a2200289 u 4500
001 EB002096264
003 EBX01000000000000001236354
005 00000000000000.0
007 cr|||||||||||||||||||||
008 221013 ||| eng
100 1 |a Ganslandt, Mattias 
245 0 0 |a Parallel imports of pharmaceutical products in the European Union  |h Elektronische Ressource  |c Mattias Ganslandt and Keith E. Maskus 
260 |a Washington, D.C  |b World Bank, Development Research Group, Trade  |c 2001 
653 |a Drugs / Prices / European Union countries / Econometric models 
653 |a Price regulation / European Union countries / Econometric models 
653 |a Gray market / European Union countries / Econometric models 
653 |a Imports / European Union countries / Econometric models 
653 |a Trademarks (International law) / Econometric models 
700 1 |a Maskus, Keith Eugene 
710 2 |a World Bank  |b Development Research Group 
041 0 7 |a eng  |2 ISO 639-2 
989 |b WOBA  |a World Bank E-Library Archive 
490 0 |a Policy research working paper 
500 |a "July 2001. - Includes bibliographical references (p. 22). - Title from title screen as viewed on Sept. 07, 2002 
856 4 0 |u http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-2630  |x Verlag  |3 Volltext 
082 0 |a 330 
520 |a Parallel imports are legitimately produced goods imported legally into a country without the authorization of a trademark, copyright, or patent holder. In the European Union, so long as a pharmaceutical manufacturer has placed a good on the market voluntarily, the principle of free movement of goods allows individuals or firms within the EU to trade goods across borders without the consent of the producer. What is the effect of these parallel imports?